title: Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
authors.affiliation: Division of Neurology, Sunnybrook Health Sciences Center, Room A402, 2075 Bayview Ave, Toronto, Ontario, Canada M4N 3M5. james.perry@sunnybrook.ca
authors.forename: James R
authors.initials: JR
authors.lastname: Perry
authors.forename: Karl
authors.initials: K
authors.lastname: Bélanger
authors.forename: Warren P
authors.initials: WP
authors.lastname: Mason
authors.forename: Dorcas
authors.initials: D
authors.lastname: Fulton
authors.forename: Petr
authors.initials: P
authors.lastname: Kavan
authors.forename: Jacob
authors.initials: J
authors.lastname: Easaw
authors.forename: Claude
authors.initials: C
authors.lastname: Shields
authors.forename: Sarah
authors.initials: S
authors.lastname: Kirby
authors.forename: David R
authors.initials: DR
authors.lastname: Macdonald
authors.forename: David D
authors.initials: DD
authors.lastname: Eisenstat
authors.forename: Brian
authors.initials: B
authors.lastname: Thiessen
authors.forename: Peter
authors.initials: P
authors.lastname: Forsyth
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Pouliot
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage* / Q000009:adverse effects; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D002170:Canada; D017024:Chemotherapy, Adjuvant; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018714:Radiotherapy, Adjuvant; D012008:Recurrence; D000077204:Temozolomide; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide